Compounding • GLP-1 • Consumer Protection • Litigation

Proposed Consumer Class Action Challenges Empower’s Compounded GLP-1 Marketing

A newly accessible October 30 complaint in New Jersey federal court alleges that two Empower entities misled consumers about the clinical evidence, personalization, and quality of compounded semaglutide and tirzepatide. The plaintiffs bring state-law claims and seek class certification, corrective advertising, and monetary relief. The complaint states the plaintiffs’ allegations. Both defendants filed waivers of service November 6, and the public docket lists January 4, 2027, as their answer deadline. The filing gives pharmacy and telehealth teams a reason to review whether their marketing claims describe the formulation patients actually receive.

By Toby C. “Chad” Frost • November 9, 2026
1 min read

What the consumers allege

Two consumers filed a proposed class action against Empower Clinic Services and Empower Clinic Services New Jersey in the U.S. District Court for the District of New Jersey on October 30, 2026. They allege that product materials used studies of FDA-approved drugs to support claims about different compounded formulations. They also challenge claims about personalization and manufacturing quality. The complaint describes injectable formulations and orally disintegrating tablets.1

What the case asks the court to decide

The plaintiffs plead state consumer protection claims, breach of express warranty, and unjust enrichment. They seek certification of a nationwide class and New York and Illinois subclasses, along with corrective advertising and monetary relief. The public docket shows waivers of service filed for both defendants on November 6 and lists January 4, 2027, as their answer deadline. The entries reviewed contain no ruling on the allegations or class certification.12

Chad’s analysis

Review marketing across the pharmacy website, product handouts, and telehealth partner materials. Match each clinical claim to evidence for the actual formulation, route, and dose being marketed. Keep the patient-specific rationale in the prescription record where applicable, and avoid relying on promotional language as a substitute for that documentation.

Source notes

  1. Class Action Complaint ¶¶ 1–8, 93–99, 100–43, at 41–42, Forcier v. Empower Clinic Servs., LLC, No. 3:26-cv-14183-RK-JBD (D.N.J. Oct. 30, 2026), ECF No. 1.
  2. Docket Entries 3–4, Forcier v. Empower Clinic Servs., LLC, No. 3:26-cv-14183-RK-JBD (D.N.J. Nov. 6, 2026), PacerMonitor public docket.